Exonate has successfully raised more than 1.5 million pounds

has successfully raised more than 1.5 million pounds to accelerate the development of its main product, an eye potion for retinal vascular disease.The announcement marks the end of its fourth round of funding, which has so far raised about 9 million pounds, with investments from Angels United, Australian venture fund Uniseed, Bristol Enterprise Fund University, Parkwalk, Cambridge Martlet, Wren Capital, O2h Ventures and other angel investors.The money raised will be used to accelerate the development of Exonate lead products, a bright spot in the treatment of retinal nevascular disease.Commenting on the announcement, Exonate CHIEF Executive Officer Dr Catherine Beech said: "I am very pleased to have completed this round of financing successfully. We would like to take this opportunity to thank our shareholders, both existing and new, for their continued support and trust in our strategy, science and team. According"Exonate", our treatment for retinal disease has the potential to significantly improve a patient's life by providing higher drug efficacy, and we have the option of going directly to current injection treatments. The funds raised will enable us to achieve the first innovative therapies for clinical development. Thelead product is expected to enter the first adaptive clinical trial of diabetic macular edema by 2020. (Compiled by this web)